Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, When Formulated With Aluminum Hydroxide, AS04, or Without Adjuvant, in Healthy Adult Female Volunteers
Latest Information Update: 03 Jul 2023
At a glance
- Drugs Aluminium hydroxide (Primary) ; AS04B (Primary) ; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 28 Sep 2016 New trial record